1-((3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)piperidine

Catalog No. :
ACMPCR249
CAS No. :
2757618-86-1
Molecular Formula :
C17H26BNO4S
Molecular Weight :
351.28

IUPAC Name:1-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)piperidine

1-((3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)piperidine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g95%$130.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-((3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)piperidine
IUPAC Name1-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)piperidine
MDL No.MFCD18915055
Molecular FormulaC17H26BNO4S
Molecular Weight351.28
SMILESO=S(N1CCCCC1)(C2=CC=CC(B3OC(C)(C)C(C)(C)O3)=C2)=O
InChI KeyHFEJTQSCKABOPB-UHFFFAOYSA-N
SynonymPiperidine, 1-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]sulfonyl]-;1-((3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)piperidine
CAS No.2757618-86-1
PubChem CID57415786

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364

Synthetic Route by SureRoute

1. ACMPCR249 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACMPCR249 route product structure diagram
    ACMPCR2492757618-86-1
Inquiry

2. ACMPCR249 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACMPCR249 route product structure diagram
    ACMPCR2492757618-86-1
Inquiry

Comments (0)